ENDRA Life Sciences Inc. — Director's Dealing 2019

Dec 11, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2019-12-11

Reporting Person: DIGIANDOMENICO ANTHONY (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-11	Common Stock	A	100503	$0.87	Acquired	199226	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-11	Stock option (right to buy)	$0.90	A	89585	Acquired	2029-12-11	Common Stock (89585)	Direct
2019-12-11	Warrants	$0.87	A	100503	Acquired	2024-12-11	Common Stock (100503)	Direct

Footnotes

F1: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date.

F2: The Warrants were issued for no additional consideration in connection with the purchase of the common stock.